Table 1.
Summary of healthy control and PD patients used in this study.
| Patient | Sex | Sample collection at age (years) | Genotype | Status | Age at onset | Sample type | Isogenic control line | Reference |
|---|---|---|---|---|---|---|---|---|
| Ctrl 1 | F | Adult | Normal | Normal | Skin biopsy | Holmqvist et al.16 | ||
| Ctrl 2 | M | 62 | Normal | Normal | Skin biopsy | Holmqvist et al.16 | ||
| PD 1 | M | 59 | LRRK2, GBA | Parkinson’s disease | 48 | Skin biopsy | Holmqvist et al.16 | |
| PD 2 | M | 64 | LRRK2 | Parkinson’s disease | 52 | Skin biopsy | Holmqvist et al.16 | |
| PD 2 iso | M | 64 | LRRK2 corr | FPD corrected | 52 | Skin biopsy | LRRK2 (G2019S) corrected |
iPSC induced pluripotent stem cell, Ctrl control, F female, M male, LRRK2 leucine-rich repeat kinase 2, GBA acid beta-glucosidase, FPD familial Parkinson`s disease.